We are live on
!
Find out more
BC
Blackcrane Capital Portfolio holdings
AUM
$16.3M
1-Year Est. Return
19.53%
This Fund
S&P 500
This Quarter
Est. Return
+4.13%
1 Year Est. Return
-19.53%
3 Year Est. Return
+40.04%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$42.9M
AUM Growth
-$45.5M
(-52%)
Cap. Flow
-$45.5M
Cap. Flow
% of AUM
-106.21%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
9
New
–
Increased
1
Reduced
6
Closed
1
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
PROF
Profound Medical
PROF
|
+$344K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AXNX
Axonics, Inc. Common Stock
AXNX
|
+$12.7M |
| 2 |
Avita Medical
RCEL
|
+$11.1M |
| 3 |
WIX.com
WIX
|
+$5.73M |
| 4 |
IMDX
Insight Molecular Diagnostics
IMDX
|
+$5.7M |
| 5 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
+$5.16M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 58.61% |
| 2 | Technology | 41.39% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Avita Medical
RCEL
$153M
| $12M | 27.88% |
474,982
-446,681
| -48% | -$11.1M |
|
|
2
WIX.com
WIX
$2.21B
| $10.6M | 24.74% |
41,610
-20,769
| -33% | -$5.73M |
|
|
AXNX
3
DELISTED
Axonics, Inc. Common Stock
AXNX
| $6.37M | 14.86% |
124,787
-303,572
| -71% | -$12.7M |
|
4
Nice
NICE
$5.91B
| $5.89M | 13.75% |
25,952
-17,705
| -41% | -$3.77M |
|
|
PROF
5
Profound Medical
PROF
$246M
| $3.47M | 8.11% |
196,924
+21,623
| +12% | +$344K |
|
|
BHVN
6
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $2.87M | 6.69% |
44,112
-78,753
| -64% | -$5.16M |
|
7
Microsoft
MSFT
$2.98T
| $1.24M | 2.9% |
5,904
-8,135
| -58% | -$1.71M |
|
8
Takeda Pharmaceutical
TAK
$53.4B
| $459K | 1.07% |
25,723
| – | – |
|
|
IMDX
9
Insight Molecular Diagnostics
IMDX
$152M
| – | – |
-149,128
| Closed | -$5.7M |
|
Similar funds
FQ
AG
SCM
CFG
YEPV
WIA
LSM
FFIM
Blackcrane Capital's Q3 2020 Portfolio in Review
As of Q3 2020, Blackcrane Capital held 9 positions worth $42.9M, down 52% from $88.4M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Blackcrane Capital withdrew a net $45.5M in Q3 2020, closing 1 position and reducing 6 holdings. Its most notable exit was Insight Molecular Diagnostics, an estimated $5.7M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 59% of assets, down from 69% a quarter earlier, followed by Technology.
Against the trend, Blackcrane Capital added an estimated $344K to Profound Medical.
- Blackcrane Capital added most to Profound Medical in Q3 2020, an estimated $344K increase.
- Blackcrane Capital's biggest Q3 2020 reduction was Axonics, Inc. Common Stock, cutting an estimated $12.7M.
- Blackcrane Capital fully exited Insight Molecular Diagnostics in Q3 2020, selling an estimated $5.7M.
- Blackcrane Capital's ten largest holdings make up 100% of its $42.9M portfolio in Q3 2020.
- Blackcrane Capital opened 0 new positions and closed 1 in Q3 2020.
- Blackcrane Capital's portfolio value fell 52% quarter-over-quarter to $42.9M.
Based on Blackcrane Capital's 13F filing for Q3 2020, filed 12 Nov 2020.